TY - JOUR T1 - Ultrasensitive measurement of both SARS-CoV2 RNA and serology from saliva JF - medRxiv DO - 10.1101/2021.01.25.21249679 SP - 2021.01.25.21249679 AU - Dmitry Ter-Ovanesyan AU - Tal Gilboa AU - Roey Lazarovits AU - Alexandra Rosenthal AU - Xu G. Yu AU - Jonathan Z. Li AU - George M. Church AU - David R. Walt Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/26/2021.01.25.21249679.abstract N2 - Tests for COVID-19 generally measure SARS-CoV2 viral RNA from nasal swabs or antibodies against the virus from blood. It has been shown, however, that both viral particles and antibodies against those particles are present in saliva, which is more accessible than both swabs and blood. We present methods for highly sensitive measurements of both viral RNA and serology from the same saliva sample. We developed an efficient saliva RNA extraction method and combined it with an ultrasensitive serology test based on Single Molecule Array (Simoa) technology. We apply our test to the saliva of patients who presented to the hospital with COVID-19 symptoms, some of whom tested positive with a conventional RT-qPCR nasopharyngeal swab test. We demonstrate that combining viral RNA detection by RT-qPCR with serology identifies more patients as infected than either method alone. Our results suggest the utility of combining viral RNA and serology testing from saliva, a single easily accessible biofluid.Competing Interest StatementDRW has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company and also serves on its Board of Directors. His interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies. GMC commercial interests: http://arep.med.harvard.edu/gmc/tech.htmlFunding StatementThis work has been funded by a grant from the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All saliva samples were collected under approval of the Mass General Brigham Institutional Review Board for Human Subjects Research. Patient samples were obtained through IRB Protocol #: 2020P000804 titled "Clinical Assessment and Sampling of Individuals with or at risk for Coronavirus Disease 2019 (COVID-19)." All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available upon request. ER -